IN2012CN10925A - - Google Patents
Info
- Publication number
- IN2012CN10925A IN2012CN10925A IN10925CHN2012A IN2012CN10925A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A IN 10925CHN2012 A IN10925CHN2012 A IN 10925CHN2012A IN 2012CN10925 A IN2012CN10925 A IN 2012CN10925A
- Authority
- IN
- India
- Prior art keywords
- trifluoromethyl
- phenyl
- ethyl
- amino
- methyl
- Prior art date
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- ZKOSMBDFOKHXLU-UHFFFAOYSA-N 2-(2-methylsulfonylethoxy)pyrimidine Chemical compound CS(=O)(=O)CCOC1=NC=CC=N1 ZKOSMBDFOKHXLU-UHFFFAOYSA-N 0.000 abstract 1
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 abstract 1
- 102000000853 LDL receptors Human genes 0.000 abstract 1
- 108010001831 LDL receptors Proteins 0.000 abstract 1
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010128585 | 2010-06-04 | ||
| JP2010218299 | 2010-09-29 | ||
| PCT/JP2011/062751 WO2011152508A1 (ja) | 2010-06-04 | 2011-06-03 | 光学活性ジベンジルアミン誘導体及びその製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012CN10925A true IN2012CN10925A (es) | 2015-04-24 |
Family
ID=45066863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10925CHN2012 IN2012CN10925A (es) | 2010-06-04 | 2011-06-03 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8906895B2 (es) |
| EP (1) | EP2578574B1 (es) |
| JP (1) | JP5555320B2 (es) |
| KR (2) | KR20170078865A (es) |
| CN (2) | CN102933559B (es) |
| AU (1) | AU2011259929B2 (es) |
| BR (1) | BR112012030787A2 (es) |
| CA (1) | CA2801417C (es) |
| EA (1) | EA024241B1 (es) |
| ES (1) | ES2581557T3 (es) |
| IL (1) | IL223377A (es) |
| IN (1) | IN2012CN10925A (es) |
| MX (1) | MX338024B (es) |
| PT (1) | PT2578574E (es) |
| TW (1) | TWI492749B (es) |
| WO (1) | WO2011152508A1 (es) |
| ZA (1) | ZA201209372B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012046681A1 (ja) * | 2010-10-04 | 2012-04-12 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
| WO2012011516A1 (ja) * | 2010-07-22 | 2012-01-26 | 興和株式会社 | 光学活性１－ブロモ－１－［３，５－ビス（トリフルオロメチル）フェニル］エタンの製造方法 |
| WO2013080999A1 (ja) * | 2011-11-29 | 2013-06-06 | 興和株式会社 | ＮＰＣ１Ｌ１及び／又はＬＩＰＧ ｍＲＮＡの発現抑制剤並びに肥満症の予防及び／又は治療剤 |
| WO2013081087A1 (ja) * | 2011-12-02 | 2013-06-06 | 興和株式会社 | 光学活性化合物の製造方法 |
| JPWO2013137371A1 (ja) * | 2012-03-15 | 2015-08-03 | 興和株式会社 | 新規ピリミジン化合物及びそれらを含有する医薬 |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| SG11201507496UA (en) | 2013-04-17 | 2015-11-27 | Pfizer | N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases |
| WO2014192903A1 (ja) | 2013-05-31 | 2014-12-04 | 興和株式会社 | ジベンジルアミン構造を有するピリミジン化合物の新規形態 |
| WO2016029037A1 (en) * | 2014-08-21 | 2016-02-25 | Srx Cardio, Llc | Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(pcsk9) protein activity |
| TWI691331B (zh) * | 2014-09-26 | 2020-04-21 | 日商興和股份有限公司 | 脂質異常症治療劑 |
| JPWO2016084949A1 (ja) * | 2014-11-28 | 2017-09-07 | 興和株式会社 | 医薬 |
| JPWO2016084950A1 (ja) * | 2014-11-28 | 2017-09-07 | 興和株式会社 | 医薬組成物 |
| JP2019131472A (ja) * | 2016-05-31 | 2019-08-08 | 興和株式会社 | 医薬組成物 |
| US11248001B2 (en) * | 2019-01-18 | 2022-02-15 | Astrazeneca Ab | PCSK9 inhibitors and methods of use thereof |
| EA202191890A1 (ru) | 2019-01-18 | 2022-02-03 | Астразенека Аб | Ингибиторы pcsk9 и способы их применения |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189208A (en) * | 1991-07-01 | 1993-02-23 | Ethyl Corporation | Ibuprofen resolution |
| MX2009010962A (es) * | 2007-04-13 | 2009-12-16 | Kowa Co | Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo. |
| WO2009143633A1 (en) * | 2008-05-30 | 2009-12-03 | Institut De Recherches Cliniques De Montreal | Pcsk9 inhibitors and methods of use thereof |
| WO2012046681A1 (ja) | 2010-10-04 | 2012-04-12 | 興和株式会社 | 脂質代謝関連ｍＲＮＡの発現抑制剤 |
-
2011
- 2011-06-03 CA CA2801417A patent/CA2801417C/en not_active Expired - Fee Related
- 2011-06-03 PT PT117899096T patent/PT2578574E/pt unknown
- 2011-06-03 JP JP2012518458A patent/JP5555320B2/ja not_active Expired - Fee Related
- 2011-06-03 EP EP11789909.6A patent/EP2578574B1/en not_active Not-in-force
- 2011-06-03 WO PCT/JP2011/062751 patent/WO2011152508A1/ja not_active Ceased
- 2011-06-03 EA EA201291447A patent/EA024241B1/ru not_active IP Right Cessation
- 2011-06-03 KR KR1020177017703A patent/KR20170078865A/ko not_active Ceased
- 2011-06-03 IN IN10925CHN2012 patent/IN2012CN10925A/en unknown
- 2011-06-03 MX MX2012014149A patent/MX338024B/es active IP Right Grant
- 2011-06-03 CN CN201180027596.9A patent/CN102933559B/zh not_active Expired - Fee Related
- 2011-06-03 KR KR1020137000104A patent/KR20130111512A/ko not_active Ceased
- 2011-06-03 AU AU2011259929A patent/AU2011259929B2/en not_active Ceased
- 2011-06-03 CN CN201510015412.7A patent/CN104529910B/zh not_active Expired - Fee Related
- 2011-06-03 US US13/700,849 patent/US8906895B2/en not_active Expired - Fee Related
- 2011-06-03 ES ES11789909.6T patent/ES2581557T3/es active Active
- 2011-06-03 TW TW100119614A patent/TWI492749B/zh not_active IP Right Cessation
- 2011-06-03 BR BR112012030787-8A patent/BR112012030787A2/pt not_active IP Right Cessation
-
2012
- 2012-12-02 IL IL223377A patent/IL223377A/en active IP Right Grant
- 2012-12-11 ZA ZA2012/09372A patent/ZA201209372B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102933559B (zh) | 2016-01-27 |
| CN102933559A (zh) | 2013-02-13 |
| US20130225814A1 (en) | 2013-08-29 |
| CA2801417C (en) | 2017-07-11 |
| ZA201209372B (en) | 2014-02-26 |
| AU2011259929A1 (en) | 2013-01-17 |
| EP2578574A1 (en) | 2013-04-10 |
| MX338024B (es) | 2016-03-31 |
| PT2578574E (pt) | 2016-06-17 |
| EP2578574B1 (en) | 2016-04-27 |
| CA2801417A1 (en) | 2011-12-08 |
| CN104529910A (zh) | 2015-04-22 |
| BR112012030787A2 (pt) | 2020-09-01 |
| TW201208688A (en) | 2012-03-01 |
| AU2011259929B2 (en) | 2014-07-31 |
| JPWO2011152508A1 (ja) | 2013-08-01 |
| WO2011152508A1 (ja) | 2011-12-08 |
| KR20170078865A (ko) | 2017-07-07 |
| ES2581557T3 (es) | 2016-09-06 |
| CN104529910B (zh) | 2017-05-10 |
| IL223377A (en) | 2016-12-29 |
| EA024241B1 (ru) | 2016-08-31 |
| EP2578574A4 (en) | 2013-12-04 |
| US8906895B2 (en) | 2014-12-09 |
| MX2012014149A (es) | 2013-02-27 |
| JP5555320B2 (ja) | 2014-07-23 |
| KR20130111512A (ko) | 2013-10-10 |
| TWI492749B (zh) | 2015-07-21 |
| HK1179959A1 (en) | 2013-10-11 |
| EA201291447A1 (ru) | 2013-05-30 |
| IL223377A0 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX338024B (es) | Derivado de dibencilamina opticamente activa y metodo para prepararla. | |
| TN2012000512A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| TN2012000511A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies | |
| MA34818B1 (fr) | Anticorps anti-pcsk9 et procédés d'utilisation | |
| AR094204A1 (es) | Composiciones para el cuidado oral que contienen haluros de acido amino | |
| WO2012170607A3 (en) | Use of pcsk9 antagonists | |
| AR059964A1 (es) | Metodos para reducir la aglomeracion de proteina | |
| AR094077A1 (es) | Composiciones de dos componentes que contienen complejos de haluro de zinc tetrabasico - aminoacido y cisteina | |
| EP2758529A4 (en) | METHOD AND COMPOSITIONS FOR REGULATING ER TRANSGENEXPRESSION | |
| MX388981B (es) | Inhibidores de enzima 1 dependiente de inositol (ire-1alfa). | |
| PH12014500122A1 (en) | Inhibitors of bruton's tyrosine kinase | |
| IN2014CN02527A (es) | ||
| UY32649A (es) | "sales de 4-(dimetilamino)butil 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato" | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| NZ605873A (en) | Methods and compositions for cns delivery of arylsulfatase a | |
| MA28985B1 (fr) | Analogues de loxapine et methodes d'utilisation | |
| EA201591379A1 (ru) | Липопротеин-ассоциированные ингибиторы фосфолипазы a2 (lp-pla) на основе 2,3-дигидроимидазо[1,2-с]пиримидин-5(1h)-онов | |
| HN2008001859A (es) | Sales de n-hodroxi-3-{4-{{{2-(2-metil-1h-indol-3-il)etil}metil}fenil}-2e--2-propenamida. | |
| BR112014002173A2 (pt) | proteínas purificadas | |
| ATE547110T1 (de) | Verwendung von zellen aus fettgewebe zur herstellung eines antitumoralen medikaments | |
| EP1740183B8 (en) | Novel use for pde5 inhibitors | |
| PH12014500054A1 (en) | Formulations that stabilize proteins | |
| EP2692734A4 (en) | Cell Adhesion | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| PH12014501304A1 (en) | Oral care compositions |